picropodophyllin has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asosingh, K; Axelson, M; De Raeve, H; Girnita, L; Jernberg-Wiklund, H; Larsson, O; Menu, E; Nilsson, K; Stromberg, T; Van Camp, B; Vanderkerken, K | 1 |
| Axelson, M; Coulton, L; Croucher, P; De Leenheer, E; De Raeve, H; Gallagher, O; Jernberg-Wiklund, H; Larsson, O; Menu, E; Nilsson, K; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K | 1 |
2 other study(ies) available for picropodophyllin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.
Topics: Animals; Bone Marrow; Cell Proliferation; Disease Models, Animal; Enzyme Activation; In Vitro Techniques; Insulin-Like Growth Factor I; Mice; Mice, Inbred C57BL; Microcirculation; Mitogen-Activated Protein Kinase 1; Multiple Myeloma; Neovascularization, Pathologic; Paraproteins; Phosphorylation; Podophyllotoxin; Receptor, IGF Type 1; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2006 |
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Disease Models, Animal; Kaplan-Meier Estimate; Mice; Multiple Myeloma; Neovascularization, Pathologic; Podophyllotoxin; Receptor, IGF Type 1 | 2007 |